BioProcess International Conference and Exhibition Starts Next Week!

Next week, over 1,500 bioprocess professionals are gathering in Boston for the industry's #1 bioprocessing event at BioProcess International Conference and Exhibition. Four days of content will will focus on cell culture & upstream processing, recovery & purification, biologics manufacturing strategies, analytical and quality, and formulation and drug delivery. Who else has registered to join us?

Here's some of the companies:

3M Purification, Abbvie. Alexion Pharmaceuticals Inc, Baxter Healthcare Corporation, BD Biosciences, Bio Rad Laboratories, BioProcess Technology Consultants, Bristol Myers Squibb, Chromatan Corporation, Corning Inc, EMD Millipore, Entegris, Eppendorf, Fujifilm Diosynth Biotechnologies, Genentech Incorporated, Hydranautics, Integra Companies Inc, JNC Corporation, Lonza, Merck & Co Inc, Momenta Pharmaceuticals, North Carolina State University, Parker Domnick Hunter, Progentics, Regeneron Pharmaceuticals, SAFC Biosciences, Shire, Takeda Pharmaceutical, United Therapeutics Corporation, VWR International LLC, WuXi AppTec

See a more comprehensive list at the webpage.

Want to join us?  As a reader of this blog, you can still save 20% off standard rates!  Register with priority code BPI14BLOG.  Have any questions?  Email me at jpereira@iirusa.com

Share this article with your social network, just click below to share now!

Share |

India and it's possible future as a biologics manufacturing leader

India is one of the premier places for biologics and drugs in the world  for the production and manufacturing of drugs.  However, with the need and demand rising both within and outside of the country could turn the Pharma and Biotech sector into an industry that grosses over $100 billion by 2025.  However, according to get to that number, Kiran Mazumdar Shaw of Bitcon in a piece written for The Financial Express believes that growth will come from manufacturing, innovation and entrepreneurship.

How can manufacturing play in to the growth of the biologics industry in India?  It's already one of Pharma's big hubs for manufacturing as it has such as cost effective rate to provide medication.  The country needs $10 billion in exports and should continue to grow.  By 2025, this number could skyrocket and Shaw sees new tax incentives from the government as a large part of that including elimination of service tax on manufacturing services provided to international clients, interest subsidies and long-term loans will also give the industry a much-needed boost. 

The investment required to create biologics is something that India needs to move forward on.  As the industry already has a significant stake in the production market, Shaw makes a significant point that investing and incentivising companies to expand and manufacture their products is an important part of future success in India.

Later this year at BioProcess International, we'll have a full track dedicated to the landscape of manufacturing.  We'll hear from GlaxoSmithKline on how they are transforming biopharmaceutical manufacturing, Novartis Vaccines & Diagnostics on how they are planning to prepare for the future pipeline of the biomanufacturing and more.  Find out more about these sessions and the rest of the program, download the agenda.  If you'd like to join us this October 20-23, 2014 in Boston for these sessions, as a reader of this blog, when you register to join us and mention code BPI14JP, you'll save 20% off the standard rate!  Have any questions or want to get involved?  Reach out to Jennifer Pereira.

Do you see India growing as a hub for biologics manufacturing?  If not, what do you see as the next manufacturing hub?

Share this article with your social network, just click below to share now!

Share |

BioProcess International 2014 takes the Industry’s Largest Event to New Heights

BPI 2014 to feature the new “BPI Theater” showcasing the industry’s hottest new products and innovation, interactive idea exchange sessions and access to partnering360® to create and build relationships

IBC Life Sciences, division of Informa, today announced that the 11th annual BioProcess International (BPI) conference & exhibition will be held from October 20-23 at the Hynes Convention Center in Boston, MA. BPI is the largest annual event where all segments involved in the development and manufacture of biologics gather to network, collaborate and learn about the most advanced bio-processing methods. This year’s BPI event promises to be the largest and most dynamic edition yet with more than 1500 delegates from around the world, five keynotes presentations, 160 speakers, 80+ posters and 150+ exhibitors.

“At GE Healthcare we are looking for an understanding of bioprocessing from start to finish, from cells to formulated drug substance. Going to BPI we see all of these aspects represented in the program and meet all those people working across that value chain,” said Guenter Jagschies, Ph.D. Senior Director, Strategic Customer Relations, GE Healthcare Life Sciences, Sweden. “BPI is an ideal event where our ideas meet those of our customers and peers.”

The conference program covers the full BioProcess spectrum including upstream processing, downstream processing, formulation and delivery, manufacturing strategy, analytical and quality and a new early stage company session on moving quickly from IND to the clinic.

In addition, BPI features four one-day pre-conference symposiums and four two-day intensive training courses on ADCs, cell therapy bioprocessing, knowledge management, process development, quality risk management, CMC analytical, comparability and stability studies, technology transfer and introduction to biopharmaceutical manufacturing. Download the agenda to see the full program.

This year’s BPI exhibit hall will feature the BPI Theater, designed to showcase the industry’s latest products and innovations. The theater will host live product demonstrations, panel discussions, rebroadcast keynote presentations and host live interviews with leading thought-leaders.

Featured in the BPI Theater will be companies who are in the forefront enabling the development of new biological products with new product launches, including Pall Life Sciences, Meissner Filtration and Sartorius Stedim Biotech.

Another powerful feature of this year’s event is the addition of partnering360®, the largest online network of life science dealmakers. Delegates will be granted exclusive access to a BPI specific partnering360® networking tool that will enable them to identify and schedule meetings with potential partners, and foster deeper engagement before, during and following the event.

Significant partnering opportunities exist for biopharmaceutical firms developing new and improved biologics including mAbs, vaccines, ADCs, recombinant proteins, bispecifics, enzymes, biosimilars and cell/gene therapy.

About IBC Life Sciences
IBC Life Sciences, a division of Informa, is your connection to the life sciences industry. Through conferences, webinars, podcasts and its suite of integrated marketing solutions, IBC Life Sciences delivers expert knowledge, valuable connections and customized offerings so customers can meet their goals. www.IBCLifeSciences.com 

IBC Life Sciences hosts the annual BioProcess International™ (BPI) Conference and Exhibition. The BioProcess International Conference & Exhibition is where the biologics value chain meets to do business. Each year BPI attracts over 1500 biologics industry leaders for four days of power networking and learning. No other industry event delivers the high-level connections and insight needed to accelerate your business. Use this preeminent industry platform to showcase your company, products and thought leadership. To get involved, visit www.IBCLifeSciences.com/BPI

Contact: Dawn O’Connor; Senior Marketing Manager; IBC Life Sciences

Share this article with your social network, just click below to share now!

Share |

IBC Life Sciences Announces Plans to Make Biopharmaceutical Development & Production (BDP) Week the Most Comprehensive Concept-to-Commercialization Conference Experience

BDP Week 2015 to incorporate content from these targeted IBC Life Sciences’ conferences: Flexible Facilities, Environmental Monitoring and Contamination Control and Single-Use Applications.


Biopharmaceutical Development & Production (BDP) Week will now be combined with the 12th Annual Single-Use Applications for Biopharmaceutical Manufacturing; 3rd Annual Flexible Facilities; and, 2nd Annual Environmental Monitoring and Contamination Control events. This expanded BDP Week will be held March 30 – April 2, 2015, at the Hyatt Regency Huntington Beach Resort & Spa in Huntington Beach, CA.

The trend in the industry is seeing companies rapidly scaling up toward commercial-scale manufacturing utilizing single-use platforms in more flexible facilities with novel monitoring and control systems. A major contributor to reducing timelines is the integration between process development, analytical and production departments to collectively overcome the complex drug manufacturing challenges to ultimately get these sensitive biologics to market.

“We are reinforcing our manufacturing programming to help companies get out front and master these new industry trends,” says Barry Walsh, Program Director, IBC Life Sciences. “By combining four of our leading biologics events we are creating the most in depth biologics manufacturing event in the industry that will deliver an unrivalled experience. Whether you’re an analytical chemist, head of process development, a manufacturing engineer or quality professional, BDP Week is the premier event to attend focused on all aspects of biologics manufacturing from clinical to commercial.”
Additionally, he said, the co-location makes for an even more productive and comprehensive conference experience for attendees and an increasingly lucrative environment for sponsors and exhibitors.

For more than a decade, BDP Week and its predecessor Antibody Development and Production have provided biopharmaceutical professionals with knowledge they need for development and regulatory landscape navigation from the bench to market. The addition of Single-Use, Flexible Facilities and Environmental Monitoring and Contamination Control not only reinforces BDP Week as the most comprehensive biologics manufacturing event on the market, but also IBC Life Sciences’ commitment to providing its attendees, sponsors and exhibitors with the best possible development opportunities available.

About IBC Life Sciences
IBC Life Sciences, a division of Informa, leads the market by providing quality, expert-led conferences and offering integrated marketing solutions to our customers. Since 1987, the leading pharmaceutical, biotechnology, government and academic organizations have recognized the high quality, in-depth content IBC Life Sciences offers.
Learn more at www.IBCLifeSciences.com.

Share this article with your social network, just click below to share now!

Share |

Take Part in 2 Interactive Flexible Facility Discussions

IBC’s Flexible Facilities brings together senior level executive and scientists from biopharmas, CMO’s, technology providers, engineering firms and regulatory groups to explore the changing landscape of biologics manufacturing - so what better place to get all the answers you need and take part in these two interactive discussions! 

Functionally-Closed Processing in CNC Environments: What is Holding Us Back? 

• What defines a closed system? 

• How closed is closed in a closed system process? 

• Regulatory perspectives in closed systems 

Panelists: 

Marc Pelletier, Ph. D., Directory of Biotechnology, CRB Consulting Engineers 

Scott Probst, Ph.D., Group Head, HealthCare and Biotechnology, Bayer Technology Services, Germany Sebastien Ribault, Ph.D., Director, Bioproduction and Development, Merck Millipore, France 

Where Do You Have to Compromise When Designing and Implementing a Flexible Facility? 

• What facility design criteria are most important for your product portfolio? 

• How to balance optimal facility needs with accelerated timelines and limited resources? 

• What compromises should you never make when designing your facility? 

Moderator: 

R. Thomas Warf, Director, Manufacturing, Facilities & Engineering, BARDA, U.S. Department of Health & Human Services 

Panelists: 

Chris McDonald, Site Head, Holly Springs Site, Novartis Vaccines and Diagnostics 

Vijay Yabammavar, Ph.D., Senior Vice President, Manufacturing Operations and Process & Analytical Development, Emergent BioSolutions 

Andrew Strong, President and CEO, Kalon Biotherapeutics 

Andrew Graham, Senior Director, Operations-Manufacturing, Nanotherapeutics, Inc. 

Want to learn more? Download our agenda.

Register with priority code FLEX14BLOG to save 20% off of our standard rate. If you have questions about the event, feel free to contact our group manager, Kate Devery (Kdevery@iirusa.com), or visit our webpage. We look forward to seeing you February 24-25 in Berkeley, California! 

Cheers, 

The Flexible Facilities Team 

Opt-in for updates

Follow us on Twitter

Flexible Facilities LinkedIn Group

Share this article with your social network, just click below to share now!

Share |

Biopharmaceutical Pipelines and Facility Needs are Changing… Are You Prepared?

IBC's 2nd Annual Flexible Facilities conference brings together senior level executives and scientists from biopharmas, CMO's, technology providers, engineering firms and regulatory groups to explore the changing landscape of biologics manufacturing and to share case studies of the latest flexible facility implementations, lessons learned and practical experiences.

Prepare Your Facilities and Bioprocesses for a Changing Market: 

• Rapid Deployment/Emerging Regions
• More Complex & Diverse Molecules
• Facility Designs to Save Time and money
• Make Stainless Steel More Flexible
• Implementation of Single-Use
• Mobile and Modular Concepts
• Multi-product/Multi-use Facilities
• Regulatory Views & Technology Gaps

To learn more, download the 2014 brochure.

This event sold out last year. If you are interested in attending, you can take advantage of the lowest rates available – this is a $600 standard rate savings when you register by November 15 with priority code FLEX14LA1. For any additional questions, visit our website:

If you have questions about the event, contact Kate Devery (Kdevery@iirusa.com), or visit our webpage. We look forward to seeing you February 24-25 in Berkeley, California!

Cheers,
The Future of Biopharma Team

Flexible Facilities Webpage
Follow us on Twitter
Flexible Facilities LinkedIn

Share this article with your social network, just click below to share now!

Share |